在跨学科瘤委员会讨论后的治疗坚持与软组织肉瘤的改善结果有关:Charité综合癌症中心的分析分析
Annika Strönisch1, Daniel Rau2, Silvan Wittenberg2
1Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
International journal of cancer
|October 17, 2024
概括
完全遵守跨学科瘤委员会 (ITB) 对软组织肉瘤 (STS) 治疗的建议至关重要. 由于并发症或疾病进展,无法遵守ITB计划,可显著增加STS患者的死亡率和疾病进展风险.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 辐射瘤学 辐射瘤学
背景情况:
- 在专家中心集中软组织肉瘤 (STS) 治疗,并利用跨学科瘤委员会 (ITB) 改善了护理.
- 然而,关于ITB建议对患者结果的实施和影响的数据仍然有限.
研究的目的:
- 分析初级STS的成年患者遵守ITB建议的情况.
- 评估坚持对患者结果的影响,包括进展和死亡率.
主要方法:
- 对222名初级STS成年患者的回顾性分析,提交给德国综合癌症中心的ITB (2015-2020).
- 检查了推的治疗方法 (切除,化疗,高热,放射治疗) 和坚持水平.
- 基于坚持的无进展生存率和总生存率的统计分析.
主要成果:
- 对ITB建议的部分遵守与明显更高的进展风险 (HR 4.0) 和死亡率 (HR 5.3) 有关.
- 由于并发症或快速进展,无法遵循ITB建议的患者表现出高风险概况,死亡率 (HR 18.1) 和进展率 (HR 21.5) 显著增加.
- 在29%的案例中,复杂的多学科概念涉及≥3种模式.
结论:
- 完全遵守ITB的建议和遵守的能力是STS患者结果的显著预后因素.
- 这项研究强调了跨学科决策和治疗规划在优化STS患者护理方面的至关重要.
- 强调需要制定战略,确保患者在专家中心遵守复杂的治疗计划.
更多相关视频
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
8.2K
07:13Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
4.2K
相关概念视频
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
